Clinical Trials Logo

Filter by:
NCT ID: NCT02943057 Active, not recruiting - Clinical trials for Cytomegalovirus Infections

Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis

Start date: October 2016
Phase: Phase 4
Study type: Interventional

25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks. Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be reviewed at the clinic within 3 hours following the last application of topical ganciclovir and clinical features will be documented for activity assessment. An aqueous sample 0.2ml is drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir drug level by HPLC method.

NCT ID: NCT02936102 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Start date: October 20, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or in combination with PDR001 in adult patients with advanced solid tumors. By blocking the interaction between Programmed Death Ligand-1 (PD-L1) and its receptors, Programmed Death-1 (PD-1) and B7.1, FAZ053 inhibits the PD-L1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells. This study has been designed as a Phase I, open-label, multi-center study with a dose escalation part of FAZ053 as single agent and in combination with PDR001, followed by a dose expansion part of FAZ053 as single agent. FAZ053 will initially be dosed every three weeks. A less frequent dosing regimen such as every 6 weeks may be evaluated in parallel. A patient may continue treatment with FAZ053 single agent or in combination with PDR001 until the patient experiences unacceptable toxicity, confirmed disease progression per immune related Response Criteria and/or treatment is discontinued at the discretion of the investigator or the patient.

NCT ID: NCT02924272 Active, not recruiting - Multiple Myeloma Clinical Trials

Ixazomib Rollover Study

Start date: December 16, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.

NCT ID: NCT02914535 Active, not recruiting - Ulcerative Colitis Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

SELECTIONLTE
Start date: February 23, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).

NCT ID: NCT02900651 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Start date: October 3, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.

NCT ID: NCT02885220 Active, not recruiting - Obesity Clinical Trials

Goal Directed Versus Conventional Weight Loss Program

Go-Pro
Start date: October 2015
Phase: N/A
Study type: Interventional

The aim of our study is to determine if the goal directed weight loss program improves weight loss versus the conventional weight loss program after laparoscopic sleeve gastrectomy.

NCT ID: NCT02872116 Active, not recruiting - Gastric Cancer Clinical Trials

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

CheckMate649
Start date: October 12, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

NCT ID: NCT02850640 Active, not recruiting - Cancer Clinical Trials

Cost and Medical Care of Patients With Advanced Serious Illness in Singapore (COMPASS) Study

COMPASS
Start date: December 2015
Phase:
Study type: Observational

Cost and Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS),is a cohort study which aims to capture health care utilization, cost, and quality of life indicators of patients with advanced cancer and their primary caregivers.

NCT ID: NCT02831712 Active, not recruiting - Clinical trials for Effect of Iron Status on Occurrence of NTBI

Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load

Start date: April 2013
Phase: N/A
Study type: Interventional

This study aims to investigate a possible effect of iron status on temporary build-up of non-transferrin bound iron (NTBI) in healthy volunteers upon iron supplementation.

NCT ID: NCT02809040 Active, not recruiting - Hypertension Clinical Trials

E_Stethoscope: Portable Digital Auscultation Study on Hypertensive/Hypertensive Heart Disease Patients

Start date: February 2015
Phase: N/A
Study type: Observational

Hypertensive heart disease (HHD) is a heart condition that is caused by chronic exposure to high blood pressure. In patients with HHD, abnormalities in the way heart muscle relaxes and how heart chambers passively fill with blood (diastolic dysfunction) can occur that may be detected on echocardiography (echo), which is a standard clinical method to examine heart structure and function using reflected sound waves. Investigators propose to develop a digital auscultation system or electronic stethoscope based on wireless sensor node technique. Investigators hypothesize that the heart sounds measurements detected by electronic stethoscope can be used to detect heart diastolic dysfunction in HHD .